Top Buy Stocks
Sign In
Invest in CMRX
$8.54
+0 (+0%)
At Close: Jun 13, 2025
Jazz Pharmaceuticals Completes Acquisition of Chimerix
04:05pm, Monday, 21'st Apr 2025
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN , April 21, 2025 /PRNewswire/ -- J
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
02:34pm, Monday, 31'st Mar 2025
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 30
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
06:00am, Friday, 21'st Mar 2025
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of C
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 07'th Mar 2025
DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
07:48am, Friday, 07'th Mar 2025
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
04:01am, Friday, 07'th Mar 2025
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
04:00pm, Thursday, 06'th Mar 2025
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
10:10am, Thursday, 06'th Mar 2025
JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
05:00pm, Wednesday, 05'th Mar 2025
NEW YORK , March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Secur
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
11:20am, Wednesday, 05'th Mar 2025
NEW YORK , March 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
08:41am, Wednesday, 05'th Mar 2025
On Tuesday, Jazz Pharmaceuticals plc JAZZ agreed to acquire Chimerix Inc CMRX for $8.55 per share in cash, representing a total consideration of approximately $935 million.
Jazz Pharmaceuticals to buy Chimerix for $935 million
07:14am, Wednesday, 05'th Mar 2025
Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday.
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
07:00am, Wednesday, 05'th Mar 2025
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- - Transaction to add near-term commercial opportunity to Jazz's pipeline- -Transaction repre
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
05:25pm, Thursday, 20'th Feb 2025
The company holds potential to have first approval of dordaviprone for the treatment of recurrent H3 K27M mutant high-grade glioma patients; PDUFA with Priority Review date of August 18th of 2025. The
